Holen Sie sich die Stockscreener-App
3.97
4.11%
-0.17
Schlusskurs vom Vortag:
$4.14
Offen:
$4.15
24-Stunden-Volumen:
1.65M
Relative Volume:
1.39
Marktkapitalisierung:
$264.11M
Einnahmen:
$488.00K
Nettoeinkommen (Verlust:
$-41.44M
KGV:
-4.2688
EPS:
-0.93
Netto-Cashflow:
$-31.47M
1W Leistung:
-7.24%
1M Leistung:
+28.06%
6M Leistung:
+16.42%
1J Leistung:
+67.86%
1-Tages-Spanne:
$3.84
$4.1866
1-Wochen-Bereich:
$3.73
$4.52
52-Wochen-Spanne:
$2.01
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Firmenname
Cardiff Oncology Inc
Sektor
Branche
Telefon
858-952-7570
Adresse
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Vergleichen Sie CRDF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
3.97 | 275.42M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-06-24 | Eingeleitet | Jefferies | Hold |
| 2024-09-06 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | William Blair | Outperform |
| 2021-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-09 | Fortgesetzt | Maxim Group | Buy |
| 2020-10-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
How strong is Cardiff Oncology Inc. company’s balance sheetUnlock superior stock analysis tools - jammulinksnews.com
Why is Cardiff Oncology Inc. stock attracting strong analyst attentionAchieve consistent profits with proven methods - jammulinksnews.com
New Product Launches: Will They Boost Cardiff Oncology Inc. Stock in 2025Free Consultation - Newser
How Interest Rate Changes Impact Cardiff Oncology Inc. Stock PerformanceFree Join Group - Newser
How Cardiff Oncology Inc. stock performs during market volatilityFree Stock Index Interpretation - Newser
Is Cardiff Oncology Inc. Stock Overbought or Oversold RSI Indicator AnalysisHigh Confidence Trade Setups - Newser
Is Cardiff Oncology Inc. stock a growth or value playFree Real-Time Trading Opportunities - Newser
Cardiff Oncology Inc. Company’s Quarterly Earnings Growth: What the Numbers SayProfit Focused Trade Alerts - Newser
When is Cardiff Oncology Inc. stock expected to show significant growthFree Consultation - jammulinksnews.com
Is Cardiff Oncology Inc. a good long term investmentHigh-octane investment gains - PrintWeekIndia
Published on: 2025-07-25 15:19:32 - PrintWeekIndia
What analysts say about Cardiff Oncology Inc. stockExplosive capital appreciation - Autocar Professional
Cardiff Oncology Inc. Stock Analysis and ForecastExplosive trading opportunities - Autocar Professional
What drives Cardiff Oncology Inc. stock priceFast-track wealth growth - jammulinksnews.com
What makes Cardiff Oncology Inc. stock price move sharplyFree Day Trading Recommendations - Newser
Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term (NASDAQ:CRDF) - Seeking Alpha
Why Cardiff Oncology Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
Cardiff Oncology (CRDF) Initiated with a Buy at Ladenburg Thalmann & Co. - The Globe and Mail
Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH - Defense World
Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $11.70 - Defense World
Cardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + Paclitaxel - MSN
Cardiff Oncology stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com Canada
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - GlobeNewswire
International Business Times - FinancialContent
Cardiff Oncology Up 16%, Insider Buyers Are Up 35% - simplywall.st
While institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the most - Yahoo Finance
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
Finanzdaten der Cardiff Oncology Inc-Aktie (CRDF)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cardiff Oncology Inc-Aktie (CRDF) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
| TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):